← Leaderboards
Timothy An-Thy Chan
Sloan-Kettering Inst Can Research
$21,076,830
Attributed
$27,759,637
Total exposure
16
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.1M · FY2011–25$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$34,040,430 · 17
By mechanism
R01$12,484,605 · 6
U54$8,246,298 · 5
R35$7,038,857 · 1
U01$3,389,732 · 1
P50$2,326,074 · 2
R21$469,503 · 1
Top collaborators
- David Sung-Wen Yu10 shared
- Naiyer A Rizvi7 shared
- Alan L. Ho6 shared
- Luc Gordon Trang Morris6 shared
- Craig B Thompson6 shared
- David A. Zidar5 shared
- Nadeem Riaz1 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Alan L. Ho$4,883,159
- Luc Gordon Trang Morris$1,605,886
- Richard N Kolesnick$17,601,323
- Sarat Chandarlapaty$10,852,142
- Jonathan Eric Rosenberg$1,981,747
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMutationGenomicsMolecularMalignant NeoplasmsGeneticMultidisciplinaryResponseResistanceImmunologicsImmuneFoundationsPhenotypeImmunotherapyBaseCellsImproved OutcomeImmune Checkpoint BlockadePathway InteractionsAffectProgramsSamplingTreatment EfficacyClinic
Grant awards (75)
Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies$1,472,071
U54 · FY2025 · CA · contact PI
Homologous recombination repair pathway mutations and genetic mechanisms shaping anti-tumor immunity and immunotherapy efficacy$713,601
R01 · FY2025 · CA · contact PI
Administrative Core$310,943
U54 · FY2025 · CA · contact PI
Project 1 Genetic and Immunologic Mechanisms Underlying Combination Sacituzumab plus Radiation Therapy for Bladder Cancer$193,244
U54 · FY2025 · CA · contact PI
Immune Oncology$85,361
P30 · FY2025 · CA · contact PI
Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies$68,003
U54 · FY2025 · CA · contact PI
Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies$1,428,130
U54 · FY2024 · CA · contact PI
Towards Precision Immuno-Oncology: Unraveling the Genomic Determinants and Mechanisms Underlying Immunotherapy Efficacy and Resistance$961,680
R35 · FY2024 · CA · contact PI
Pre-exposure Immunologic Health and Linkages to SARS-COV2 Serologic Responses, Endothelial Cell Resilience, and Cardiovascular Complications: Defining the mechanistic basis of high risk endotypes.$433,161
U01 · FY2024 · CA
Administrative Core$317,508
U54 · FY2024 · CA · contact PI
Project 1 Genetic and Immunologic Mechanisms Underlying Combination Sacituzumab plus Radiation Therapy for Bladder Cancer$209,500
U54 · FY2024 · CA · contact PI
Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies$64,603
U54 · FY2024 · CA · contact PI
Administrative Core$64,603
U54 · FY2024 · CA · contact PI
Administrative Core$33,602
U54 · FY2024 · CA · contact PI
Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies$33,602
U54 · FY2024 · CA · contact PI
Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies$1,473,606
U54 · FY2023 · CA · contact PI
Towards Precision Immuno-Oncology: Unraveling the Genomic Determinants and Mechanisms Underlying Immunotherapy Efficacy and Resistance$992,049
R35 · FY2023 · CA · contact PI
Pre-exposure Immunologic Health and Linkages to SARS-COV2 Serologic Responses, Endothelial Cell Resilience, and Cardiovascular Complications: Defining the mechanistic basis of high risk endotypes.$806,907
U01 · FY2023 · CA
Administrative Core$247,394
U54 · FY2023 · CA · contact PI
Project 1 Genetic and Immunologic Mechanisms Underlying Combination Sacituzumab plus Radiation Therapy for Bladder Cancer$164,648
U54 · FY2023 · CA · contact PI
Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies$70,904
U54 · FY2023 · CA · contact PI
Administrative Core$70,904
U54 · FY2023 · CA · contact PI
Project 3 Molecular Mechanisms Underlying Therapy Response to Radiation and Immune Checkpoint Blockade$66,643
U54 · FY2023 · CA · contact PI
Administrative Core$66,643
U54 · FY2023 · CA · contact PI
Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies$36,982
U54 · FY2023 · CA · contact PI
Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies$1,566,249
U54 · FY2022 · CA · contact PI
Towards Precision Immuno-Oncology: Unraveling the Genomic Determinants and Mechanisms Underlying Immunotherapy Efficacy and Resistance$992,049
R35 · FY2022 · CA · contact PI
Pre-exposure Immunologic Health and Linkages to SARS-COV2 Serologic Responses, Endothelial Cell Resilience, and Cardiovascular Complications: Defining the mechanistic basis of high risk endotypes.$673,696
U01 · FY2022 · CA
Identifying and targeting neoantigens in aggressive salivary carcinomas$455,430
R01 · FY2022 · DE
Project 1 Genetic and Immunologic Mechanisms Underlying Combination Sacituzumab plus Radiation Therapy for Bladder Cancer$193,243
U54 · FY2022 · CA · contact PI
Pre-exposure Immunologic Health and Linkages to SARS-COV2 Serologic Responses, Endothelial Cell Resilience, and Cardiovascular Complications: Defining the mechanistic basis of high risk endotypes.$117,120
U01 · FY2022 · CA
Administrative Core$93,273
U54 · FY2022 · CA · contact PI
Towards Precision Immuno-Oncology: Unraveling the Genomic Determinants and Mechanisms Underlying Immunotherapy Efficacy and Resistance$865,728
R35 · FY2021 · CA · contact PI
Identifying and targeting neoantigens in aggressive salivary carcinomas$506,762
R01 · FY2021 · DE
Elucidating genetics of response to immune checkpoint blockade in lung cancer$418,751
R01 · FY2021 · CA · contact PI
Elucidating genetics of response to immune checkpoint blockade in lung cancer$203,550
R01 · FY2021 · CA
Identifying and targeting neoantigens in aggressive salivary carcinomas$101,802
R01 · FY2021 · DE
Pre-exposure Immunologic Health and Linkages to SARS-COV2 Serologic Responses, Endothelial Cell Resilience, and Cardiovascular Complications: Defining the mechanistic basis of high risk endotypes.$1,358,848
U01 · FY2020 · CA
Towards Precision Immuno-Oncology: Unraveling the Genomic Determinants and Mechanisms Underlying Immunotherapy Efficacy and Resistance$1,033,264
R35 · FY2020 · CA · contact PI
Elucidating genetics of response to immune checkpoint blockade in lung cancer$558,644
R01 · FY2020 · CA
Identifying and targeting neoantigens in aggressive salivary carcinomas$545,430
R01 · FY2020 · DE
TOWARDS PRECISION IMMUNO-ONCOLOGY: UNRAVELING THE GENOMIC DETERMINANTS AND MECHANISMS UNDERLYING IMMUNOTHERAPY EFFICACY AND RESISTANCE$161,000
R35 · FY2020 · CA · contact PI
Towards Precision Immuno-Oncology: Unraveling the Genomic Determinants and Mechanisms Underlying Immunotherapy Efficacy and Resistance$798,543
R35 · FY2019 · CA · contact PI
Identifying and targeting neoantigens in aggressive salivary carcinomas$592,082
R01 · FY2019 · DE
Elucidating genetics of response to immune checkpoint blockade in lung cancer$541,884
R01 · FY2019 · CA
Elucidating and targeting the molecular foundations of IDH mutant glioma$477,777
R01 · FY2019 · CA · contact PI
RP-3: Elucidating Mechanisms of Sensitivity and Resistance to Checkpoint Blockade Therapy for Rational Multi-Drug Immunotherapy in Urothelial Cancers$343,314
P50 · FY2019 · CA · contact PI
Towards Precision Immuno-Oncology: Unraveling the Genomic Determinants and Mechanisms Underlying Immunotherapy Efficacy and Resistance$193,694
R35 · FY2019 · CA · contact PI
Elucidating and targeting the molecular foundations of IDH Mutant glioma$74,890
R01 · FY2019 · CA · contact PI
Towards Precision Immuno-Oncology: Unraveling the Genomic Determinants and Mechanisms Underlying Immunotherapy Efficacy and Resistance$1,040,850
R35 · FY2018 · CA · contact PI
Identifying and targeting neoantigens in aggressive salivary carcinomas$570,903
R01 · FY2018 · DE
Elucidating and targeting the molecular foundations of IDH mutant glioma$560,454
R01 · FY2018 · CA · contact PI
Elucidating genetics of response to immune checkpoint blockade in lung cancer$558,644
R01 · FY2018 · CA
RP-3: Elucidating Mechanisms of Sensitivity and Resistance to Checkpoint Blockade Therapy for Rational Multi-Drug Immunotherapy in Urothelial Cancers$369,155
P50 · FY2018 · CA · contact PI
Elucidating and Targeting the Molecular Foundations of Hurthle Cell Cancer$340,866
P50 · FY2018 · CA · contact PI
Elucidating genetics of response to immune checkpoint blockade in lung cancer$159,998
R01 · FY2018 · CA
Elucidating genetics of response to immune checkpoint blockade in lung cancer$573,644
R01 · FY2017 · CA
Elucidating and targeting the molecular foundations of IDH mutant glioma$562,887
R01 · FY2017 · CA · contact PI
Elucidating and Targeting the Molecular Foundations of Hurthle Cell Cancer$319,274
P50 · FY2017 · CA · contact PI
Elucidating genetics of response to immune checkpoint blockade in lung cancer$159,998
R01 · FY2017 · CA
Elucidating and targeting the molecular foundations of IDH mutant glioma$563,179
R01 · FY2016 · CA · contact PI
Elucidating and Targeting the Molecular Foundations of Hurthle Cell Cancer$318,164
P50 · FY2016 · CA · contact PI
Elucidating and targeting the molecular foundations of IDH mutant glioma$570,187
R01 · FY2015 · CA · contact PI
Role of Parkinson's disease gene PARK2 in GBM oncogenesis and genomic instability$386,750
R01 · FY2015 · NS · contact PI
Elucidating the function of the widely inactivated phosphatase PTPRD in the molec$379,518
R01 · FY2015 · CA · contact PI
Elucidating and Targeting the Molecular Foundations of Hurthle Cell Cancer$317,077
P50 · FY2015 · CA · contact PI
Role of Parkinson's disease gene PARK2 in GBM oncogenesis and genomic instability$382,882
R01 · FY2014 · NS · contact PI
Elucidating the function of the widely inactivated phosphatase PTPRD in the molec$368,132
R01 · FY2014 · CA · contact PI
Elucidating and Targeting the Molecular Foundations of Hurthle Cell Cancer$318,224
P50 · FY2014 · CA · contact PI
Role of Parkinson's disease gene PARK2 in GBM oncogenesis and genomic instability$386,750
R01 · FY2013 · NS · contact PI
Elucidating the function of the widely inactivated phosphatase PTPRD in the molec$356,746
R01 · FY2013 · CA · contact PI
The mutational landscapes underlying aggressiveness in adenoid cystic carcinoma$169,728
R21 · FY2013 · DE · contact PI
Elucidating the function of the widely inactivated phosphatase PTPRD in the molec$379,518
R01 · FY2012 · CA · contact PI
The mutational landscapes underlying aggressiveness in adenoid cystic carcinoma$299,775
R21 · FY2012 · DE · contact PI
Elucidating the function of the widely inactivated phosphatase PTPRD in the molec$373,812
R01 · FY2011 · CA · contact PI